









The GOG Highlight Reel Spring 2022

Thursday, June 9, 2022

A GOG Foundation, Inc. Educational Program













Larry J. Copeland, MD The Ohio State University, James Cancer Center & President, The GOG Foundation, Inc.









LEARNING OBJECTIVES

Upon completion of the activities in this series, learners will demonstrate:

THE OVERALL OBJECTIVE FOR THIS SESSION IS TO SHOWCASE CLINICAL TRIALS AND OTHER NEWSWORTHY EDUCATION FROM MAJOR MEDICAL MEETINGS THROUGHOUT THE YEAR

Increased knowledge regarding

- cancers
- cancers
- cervical, endometrial, and ovarian cancers

Greater competence related to

• Selecting therapies and treatments for women with cervical, endometrial, and ovarian cancers

Greater confidence in their ability to:

• Counsel patients with cervical, endometrial, and ovarian cancers on new and cutting-edge therapies



• The current agents and regimens used in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian

• The key trial data for newer therapies in treating advanced, persistent, or recurrent cervical, endometrial, and ovarian

• The current investigational agents and regimens under evaluation for the treatment of advanced, persistent, or recurrent





GOG FACULTY DISCLOSURE INFORMATION Virtual Symposium, "GOG Highlight Reel – Summer 2022 "

June 2022

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An "ineligible company" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.





GOG FACULTY DISCLOSURE INFORMATION

NAME:	Individual's Role(s) in	Nothing To	DISCLOSURE
Speaker/Moderators	Activity	Disclose	<company &="" role=""></company>
Robert Coleman, MD	Planning/Speaker		Honorarium: Abbvie, Agenus, Alkermes, As Epsilogen, Genmab/Seattle Genetics, Grad Immunogen, Janssen, Myriad,Novocure, Oncoquest, Oncologie, Roche/Genentech
Bradley J. Monk, MD	Planning/Speaker		Honoraria: Consulting/Speaker: Agenus, Ak Aravive,, Clovis, Easai, Elevar, Genmab/Se GOG Foundation. Gradalis, Iovance, Karyo McKesson, Mersana, Myriad, Novocure, Pfizer, Roche/Genentech, Sorrer VBL
Angeles Alvarez Secord, MD			Advisory Board: Myriad Contracted clinical AbbVie, AstraZeneca, Boehringer, Clovis, E Merck, National Cancer Trial Network, Once PharmaMar, Roche/Genentech, Seagen ind VBL Therapeutics
Ramez Eskander, MD			Advisory Board/Consulting Fee/Speaking: A Merck; Clovis; GSK, Myriad
Thomas Herzog, MD	Speaker	X	
Kathleen Moore, MD	Speaker		Advisory board: AstraZeneca, Aravive, Blue OnxXema, Eisai, GSK, Elevar, Genentech, Merck, VBL, Mersana, Myriad
David O'Malley, MD	Speaker		Honorarium: Roche Diagnostics, Watermar AstraZeneca, Sorrento, Rubius, Elevar, Nov GSK,Novocure, Genentech, GOG Foundati Seattle Genetics, Ambry, Regeneron, Myria GSK/Tesaro, Agenus
Bhavana Pothuri, MD	Speaker		Research funding support/ Ad Board fees: Celsion ,Immunogen, Merck, Mersana,Seat Sutro, Takada, Tesaro, Clovis Oncology Advisory Board: Eisai, Lily, GOG Foundatio
Leslie Randall, MD	Speaker		Consulting fee: Agenus, Clovis, Myriad, Me GSK/Tesaro Research Grant/ Contractor: Merck, Pfizer
Brian Slomovitz, MD	Speaker		Consultant: Abbvie, AstraZeneca, Clovis, G Merck, Myriad
Michelle Small	Staff	Х	
Jill Reese	Staff	X	

AstraZeneca, Clovis, adalis, GSK,

Akeso, AstraZeneca Seattle Genetics,, opharm, Merck,

rento, Tesaro/GSK,

cal trial research: Eisai, Immutep. Ltd ncoquest, nc., Tesaro/GSK,

AstraZeneca;

ueprint, Alkemeres, , Immunogen,

ark, Immunogen, ovartis, Eisai, ation, Mersana, riad,

AstraZeneca, attle Genetics,

on

ersana,

GSK, Genentech,

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.


The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. "Relevant" financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.


All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An "ineligible company" is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.











GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

Accreditation Statement

The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMA PRA Category 1 Credits[™]

The GOG Foundation, Inc. designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the preand post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.





COMMERCIAL SUPPORTERS

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium.






MODERATORS



Bradley J. Monk, MD

Bradley Monk, MD, Director, Principal Investigator, Community Research Development, HonorHealth Research, Institute, University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's, Hospital Phoenix, Arizona, USA



Robert Coleman, MD

US Oncology, Houston, Texas, USA









FACULTY



- Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA
- Leslie Randall, MD, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA
- David O'Malley, MD, The Ohio State University, Columbus, Ohio, USA
- Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
- Ramez Eskander, MD, UC San Diego, San Diego, California, USA
- Angeles Alvarez Secord, MD, Duke University, Durham, North Carolina, USA
- Bhavana Pothuri, MD, NYU Langone, New York City, New York, USA
- Thomas J. Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA







2:30 pm – 2: 40 pm	Welcome & Introduction Larry J. Copeland, MD, The Ohio State, Ja Bradley Monk, MD, Director, Principal In Institute, University of Arizona College of Hospital Phoenix, Arizona, USA Robert Coleman, MD, US Oncology, Hou
2:40 pm – 2:55 pm	Uterine Highlights from Spring G Brian Slomovitz, MD, Mount Sinai Medic
2:55 pm – 3:10 pm	Uterine Panel Discussion All Faculty
3:10 pm – 3:30 pm	Cervical Highlights from Spring C Leslie Randall, MD, Massey Cancer Cent
3:30 pm – 3:50 pm	Cervical Panel Discussion All Faculty

James Cancer Center & President, The GOG Foundation, Inc nvestigator, Community Research Development, HonorHealth Research of Medicine, Creighton University School of Medicine at St. Joseph's

ouston, Texas, USA

Gynecologic Meetings ical Center, Miami Beach, Florida, USA

Gynecologic Meetings

iter, Virginia Commonwealth University, Richmond, Virginia, USA









3:50 pm – 4:00 pm	Ovarian Highlights: Frontline Sen David O'Malley, MD, The Ohio State Univ
4:00 pm – 4:15 pm	Ovarian Discussion: Frontline Se All Faculty
4:15 pm – 4:25 pm	Ovarian Highlights: PROC from S Kathleen Moore, MD, Stephenson Cance
4:25 pm – 4:40 pm	Ovarian Panel Discussion: PROC All Faculty
4:40 pm – 5:00 pm	GOG Partners, Trials in Progress All Faculty
5:00 pm - 5:30 pm	The Final Word All Faculty

ensitive from Spring Gynecologic Meetings niversity, Columbus, Ohio, USA

ensitive

Spring Gynecologic Meetings

cer Center, Oklahoma City, Oklahoma, USA









THANK YOU

GO TO WWW.GOG.ORG to view this presentation through November 11, 2022













Currently what is your biggest barrier to clinical trial enrollment?

- **1.No trials open**
- **2.Staff shortage**
- **3.**Competing trials
- **4.**Reimbursement 5.Other



1. No trials open 2.Staff shortage 3.Competing trials 4. Reimbursement 5.Other



16





THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

